MP09-03 COMBINATION THERAPY OF TADALAFIL AND TAMSULOSIN FOR MEN WITH MODERATE TO SEVERE BENIGN PROSTATIC HYPERPLASIA

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical & Non-surgical Therapy1 Apr 2017MP09-03 COMBINATION THERAPY OF TADALAFIL AND TAMSULOSIN FOR MEN WITH MODERATE TO SEVERE BENIGN PROSTATIC HYPERPLASIA Hyun Jun Park, Tae Nam Kim, Jong Kil Nam, Du Geon Moon, and Nam Cheol Park Hyun Jun ParkHyun Jun Park More articles by this author , Tae Nam KimTae Nam Kim More articles by this author , Jong Kil NamJong Kil Nam More articles by this author , Du Geon MoonDu Geon Moon More articles by this author , and Nam Cheol ParkNam Cheol Park More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.311AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Benign prostatic hyperplasia (BPH) is commonly treated with alpha-blockers and 5-alpha-reductase inhibitors (5ARIs). However, tamsulosin has sexual side-effects, including ejaculatory dysfunction. Recently, tadalafil 5 mg daily has been shown to be helpful in treating lower urinary tract symptoms (LUTS). Thus, we compared tadalafil and tamsulosin with tamsulosin alone in terms of symptom improvement in males with moderate to severe BPH. METHODS This 12-week study was a randomized, parallel group evaluation of clinical outcomes in males aged ≥ 50 years with symptomatic (IPSS≥12) BPH and a prostate volume ≥ 30 mL. Eligible patients received a combination of tadalafil 5 mg daily with tamsulosin 0.4 mg daily (n=30), or tamsulosin 0.4 mg daily only (n=30). The primary outcomes included the post-treatment IPSS, peak urinary flow rate, and post-void residual urine volume. The secondary outcomes were changes in scores on the IIEF, the Global Assessment Questionnaire (GAQ), and the Life Satisfaction Checklist (LSC). RESULTS The IPSS improved similarly from baseline to 12 weeks in both groups (tadalafil+tamsulosin; -2.2 vs. tamsulosin only; -2.3; p=0.528). However, the IPSS storage subscale improved to a significantly greater extent in the tadalafil+tamsulosin group. Changes in the Q(Max) and PVR did not differ significantly between the groups. The tadalafil+tamsulosin group showed significantly greater changes in the erectile and orgasmic function domain scores of the IIEF compared to the tamsulosin-only group. In terms of the GAQ and LSC scores, the tadalafil+tamsulosin group exhibited significantly greater improvements. The adverse events profiles were consistent with those of previous reports. CONCLUSIONS Combination therapy with tadalafil and tamsulosin afforded improvements in LUTS/BPH scores similar to those seen when tamsulosin only was given. However, the combination also had obvious benefits in terms of sexual function. Tadalafil can compensate for the decreased sexual performance that is a side-effect of tamsulosin, and improve the LUTS. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e100 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Hyun Jun Park More articles by this author Tae Nam Kim More articles by this author Jong Kil Nam More articles by this author Du Geon Moon More articles by this author Nam Cheol Park More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...